Clinical Trial Update: NPC - AXEL Study : Axitinib-Avelumab [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the axitinib-avelumab combination in recurrent or metastatic nasopharyngeal carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• Avelumab (avelumab)
• Axitinib (Axitinib)

Snippet

Sponsor: Chinese University of Hong Kong | Conditions: Recurrent or Metastatic NPC | Phase 2 | Status: COMPLETED